Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 3/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.31 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
| ▸ | GPR183 | P32249 | 1/20 | 0.31 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4074908 | 0.91 | FDPS (0.41) | FDPSSMPD1ALDH1A1TNNC1S1PR1 | |
| SCHEMBL12417217 | 0.91 | FDPS (0.41) | FDPSSMPD1ALDH1A1TNNC1S1PR1 | |
| SCHEMBL19283464 | 0.91 | FDPS (0.39) | FDPSSMPD1ALDH1A1SMN1; SMN2 | |
| SCHEMBL11051714 | 0.86 | FDPS (0.34) | FDPS | |
| SCHEMBL2349277 | 0.85 | ALDH1A1 (0.38) | FDPSALDH1A1TNNC1S1PR1SGPL1 | |
| SCHEMBL8432610 | 0.85 | FDPS (0.39) | FDPSSMPD1ALDH1A1 | |
| SCHEMBL251421 | 0.85 | ALDH1A1 (0.38) | FDPSALDH1A1TNNC1S1PR1SGPL1 | |
| SCHEMBL21161 | 0.85 | ALDH1A1 (0.38) | FDPSALDH1A1TNNC1S1PR1SGPL1 | |
| SCHEMBL10313065 | 0.85 | FDPS (0.39) | FDPSSMPD1ALDH1A1 | |
| SCHEMBL2343833 | 0.85 | ALDH1A1 (0.38) | FDPSALDH1A1TNNC1S1PR1SGPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4446301-A | IMIDE FROM BRANCHED ALKANOLAMINE | EASTMAN KODAK COMPANY (US) | 1984-05-01 | — | — | US | claimed |
| US-20140161801-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2014-06-12 | — | — | US | disclosed |
| EP-0257848-A2 | Certain carbamates, processes for preparing same and use thereof | KING INDUSTRIES, INC. (US) | 1988-03-02 | — | — | EP | disclosed |
| US-4446301-A | IMIDE FROM BRANCHED ALKANOLAMINE | EASTMAN KODAK COMPANY (US) | 1984-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140161801-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | JAK1, JAK2, YES1 | FDPS 2492/4885SMPD1 3352/4885ALDH1A1 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.